First biotech IPO this year advised by Dechert

Dechert has advised on the first biotech IPO to get away in the UK this year. London partner David Vogel (left) led the team that advised Yesterday BioProgress on its admission to AIM. The company’s subsidiary BioProgress Technology International was previously listed on the US Over the Counter Bulletin Board but, as part of the deal, its existing shareholders swapped their US shares for UK shares in the new company.

First reported on, 28 May